[Federal Register Volume 72, Number 107 (Tuesday, June 5, 2007)]
[Notices]
[Page 31075]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-10740]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Advisory Committee; Risk Communication Advisory Committee; 
Establishment

AGENCY:  Food and Drug Administration

ACTION:  Notice of establishment.

-----------------------------------------------------------------------

    Under the Federal Advisory Committee Act, as amended (5 U.S.C. 
Appendix 2), the Commissioner of Food and Drugs (the Commissioner), 
announces the establishment of the Risk Communication Advisory 
Committee. The Commissioner has determined that it is in the public 
interest to establish such a committee.
    The Risk Communication Advisory Committee shall provide advice to 
the Commissioner or designee on strategies and programs designed to 
communicate with the public about both the risks and benefits of Food 
and Drug Administration (FDA)-regulated products so as to facilitate 
optimal use of these products. The committee also reviews and evaluates 
research relevant to such communication to the public by both FDA and 
other entities. It also facilitates interactively sharing risk and 
benefit information with the public to enable people to make informed 
independent judgments about use of FDA-regulated products. Duration of 
this committee is 2 years from the date the Charter is filed, unless 
the Commissioner formally determines that renewal is in the public 
interest.
    The Risk Communication Advisory Committee will be composed of a 
core of 15 voting members including the Chair. Members and the Chair 
are selected by the Commissioner or designee from among authorities 
knowledgeable in the fields of risk communication, social marketing, 
health literacy, cultural competency, journalism, bioethics, and other 
relevant behavioral and social sciences. Some members will be selected 
to provide experience-based insights on the communications needs of the 
various groups who use FDA-regulated products. The latter may include 
patients and patients' family members, health professional, 
communicators in health, medicine and science, persons affiliated with 
consumer, specific disease, or patient safety advocacy groups. 
Depending on the meeting topic(s), at least one nonvoting member 
identified with relevant industry interests may be invited from 
existing members of other FDA Advisory Committees.

FOR FURTHER INFORMATION CONTACT:  Lee Zwanziger, Office of Planning, 
Office of the Commissioner (HFP-1), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-827-2895, FAX: 301-827-5260, or 
[email protected].

SUPPLEMENTARY INFORMATION: Elsewhere in this issue of the Federal 
Register, FDA is publishing a request for nominations for advisory 
committee members and notice of a change to the advisory committee 
telephone information line adding the establishment of the Risk 
Communication Advisory Committee. FDA plans to publish in the near 
future a final rule adding the Risk Communication Advisory Committee to 
the list of FDA standing advisory committees in 21 CFR 14.100.

    Dated: May 28, 2007.
Randall W. Lutter,
Associate Commissioner for Policy and Planning.
[FR Doc. E7-10740 Filed 6-4-07; 8:45 am]
BILLING CODE 4160-01-S